|
|
|
|
The rate of dopaminergic loss in PD is significantly greater than that of healthy controls, and [123I]¯-CIT SPECT imaging provides a quantitative biomarker for the progressive nigrostriatal dopaminergic degeneration in PD. As new protective and restorative therapies for PD are developed, dopamine transporter imaging offers the potential to provide an objective endpoint for these therapeutic trials. |
|